nVerses Capital LLC Buys Shares of 300 Repligen Co. (NASDAQ:RGEN)

nVerses Capital LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 300 shares of the biotechnology company’s stock, valued at approximately $45,000.

Several other institutional investors have also modified their holdings of the business. Andra AP fonden acquired a new position in shares of Repligen during the second quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in Repligen during the second quarter worth approximately $33,000. UMB Bank n.a. lifted its position in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new position in shares of Repligen in the 2nd quarter valued at $57,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $144.14 on Wednesday. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a 50-day moving average price of $144.70 and a 200 day moving average price of $147.71. The company has a market cap of $8.07 billion, a P/E ratio of -3,602.60, a PEG ratio of 4.24 and a beta of 0.95. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.53 earnings per share. Research analysts predict that Repligen Co. will post 1.45 earnings per share for the current year.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

RGEN has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the company from $180.00 to $155.00 in a report on Wednesday, June 26th. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.